Petros Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Petros Pharmaceuticals, Inc. (PTPI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 455.07 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 299.07K shares.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was -45.00K shares.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 0.00 shares.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 455.07K shares, a 9001.32% increase from fiscal 2022.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 5.00K shares, a 91.88% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 61.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | 299.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 299.07K shares derived: sum of 2 quarters · filed 2025-03-31 | 455.07K shares 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | 156.00K shares 10-Q · filed 2023-11-15 | |||||
| 2023-06-30 | 156.00K shares 10-Q · filed 2023-08-14 | ||||||
| 2022-12-31 | -45.00K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-01 | -45.00K shares derived: sum of 2 quarters · filed 2024-04-01 | -45.00K shares derived: sum of 3 quarters · filed 2024-04-01 | 5.00K shares 10-K · filed 2024-04-01 | |||
| 2022-09-30 | 0.00 shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-15 | 50.00K shares 10-Q/A · filed 2022-11-15 | -527.40K shares derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 50.00K shares 10-Q · filed 2022-08-12 | -527.40K shares derived: sum of 3 quarters · filed 2023-03-31 | -527.40K shares derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-03-31 | 50.00K shares 10-Q · filed 2022-05-16 | -527.40K shares derived: sum of 2 quarters · filed 2023-03-31 | -527.40K shares derived: sum of 3 quarters · filed 2023-03-31 | -104.10K shares derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-01-04 | 5.00K shares 10-K · filed 2024-04-01 | 50.00K shares 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | -577.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -577.40K shares derived: sum of 2 quarters · filed 2023-03-31 | -154.10K shares derived: sum of 3 quarters · filed 2023-03-31 | 61.57K shares 10-K · filed 2023-03-31 | 615.67K shares 10-K · filed 2022-03-31 | ||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 423.30K shares derived: sum of 2 quarters · filed 2021-11-15 | 638.97K shares 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | 423.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 638.97K shares 10-Q · filed 2021-08-16 | |||||
| 2021-05-11 | 15.00K shares 10-K · filed 2023-03-31 | 150.00K shares 10-Q · filed 2021-08-16 | |||||
| 2021-03-31 | 215.67K shares 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |